Promoting innovations - World Asthma day on 5 May
NHS England and NHS Improvement are supporting World Asthma Day (5 May) by raising awareness of two Rapid Uptake Products to help individuals with asthma – biologics (reslizumab; benralizumab; mepolizumab and omalizumab) and fractional exhaled nitric oxide (FeNO) testing.
Source:
NHS Networks
SPS commentary:
Rapid Uptake Products are those with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.
The measurement of FeNO concentration in the breath of patients suspected of having asthma is a method that assists with its diagnosis. The aim of this innovation (products NIOX VERO and NObreath) will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.
Biological therapies (reslizumab, benralizumab, mepolizumab and omalizumab) can transform patient lives by reducing long-term side effects of other treatments (e.g. oral corticosteroids (OCS)) and can also reduce the number of exacerbations and life-threatening asthma attacks. The aim of this innovation will be to improve patient care and outcomes by providing a better treatment option for patients with severe asthma.